JP2007507458A5 - - Google Patents

Download PDF

Info

Publication number
JP2007507458A5
JP2007507458A5 JP2006530072A JP2006530072A JP2007507458A5 JP 2007507458 A5 JP2007507458 A5 JP 2007507458A5 JP 2006530072 A JP2006530072 A JP 2006530072A JP 2006530072 A JP2006530072 A JP 2006530072A JP 2007507458 A5 JP2007507458 A5 JP 2007507458A5
Authority
JP
Japan
Prior art keywords
beads
onto
formulation
subcoating
sprayed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006530072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507458A (ja
Filing date
Publication date
Priority claimed from GB0323202A external-priority patent/GB0323202D0/en
Priority claimed from GB0323598A external-priority patent/GB0323598D0/en
Priority claimed from GB0329852A external-priority patent/GB0329852D0/en
Priority claimed from GB0405902A external-priority patent/GB0405902D0/en
Priority claimed from GB0410714A external-priority patent/GB0410714D0/en
Priority claimed from GB0419356A external-priority patent/GB0419356D0/en
Application filed filed Critical
Priority claimed from PCT/EP2004/010998 external-priority patent/WO2005034916A1/en
Publication of JP2007507458A publication Critical patent/JP2007507458A/ja
Publication of JP2007507458A5 publication Critical patent/JP2007507458A5/ja
Pending legal-status Critical Current

Links

JP2006530072A 2003-10-03 2004-10-01 ミコフェノール酸またはミコフェノール酸ナトリウムを含む医薬多粒子組成物およびラパマイシンとの組み合わせ Pending JP2007507458A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0323202A GB0323202D0 (en) 2003-10-03 2003-10-03 Organic compounds
GB0323598A GB0323598D0 (en) 2003-10-08 2003-10-08 Organic compounds
GB0329852A GB0329852D0 (en) 2003-12-23 2003-12-23 Organic compounds
GB0405902A GB0405902D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0410714A GB0410714D0 (en) 2004-05-13 2004-05-13 Organic compounds
GB0419356A GB0419356D0 (en) 2004-08-31 2004-08-31 Organic compounds
PCT/EP2004/010998 WO2005034916A1 (en) 2003-10-03 2004-10-01 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin

Publications (2)

Publication Number Publication Date
JP2007507458A JP2007507458A (ja) 2007-03-29
JP2007507458A5 true JP2007507458A5 (OSRAM) 2007-11-22

Family

ID=34437795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530072A Pending JP2007507458A (ja) 2003-10-03 2004-10-01 ミコフェノール酸またはミコフェノール酸ナトリウムを含む医薬多粒子組成物およびラパマイシンとの組み合わせ

Country Status (11)

Country Link
US (1) US20070036857A1 (OSRAM)
EP (1) EP1670437A1 (OSRAM)
JP (1) JP2007507458A (OSRAM)
AR (1) AR045957A1 (OSRAM)
AU (1) AU2004280078B2 (OSRAM)
BR (1) BRPI0414864A (OSRAM)
CA (1) CA2538099A1 (OSRAM)
MX (1) MXPA06003646A (OSRAM)
PE (1) PE20050755A1 (OSRAM)
TW (1) TW200520759A (OSRAM)
WO (1) WO2005034916A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210787B2 (en) 2002-02-01 2009-04-23 Medinol Ltd. Phosphorus-containing compounds & uses thereof
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2640283A1 (en) * 2006-02-13 2007-08-23 Novartis Ag High dosage of mycophenolic acid (mpa)
EP2094241A4 (en) * 2006-11-14 2013-04-17 Ariad Pharma Inc ORAL FORMULATIONS
MX2010001711A (es) * 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
AU2009220779A1 (en) * 2008-03-05 2009-09-11 Panacea Biotec Limited Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
AU2010264116B2 (en) * 2009-06-25 2013-12-19 Dupont Nutrition Biosciences Aps Protein
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
PH12014500746A1 (en) 2011-10-06 2019-07-17 Novartis Ag Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
WO2014059309A1 (en) * 2012-10-11 2014-04-17 Theravida, Inc. Pharmaceutical formulations of pilocarpine
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
WO2014167442A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MA40982A (fr) 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
CN107847491A (zh) 2015-05-20 2018-03-27 诺华公司 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
JP7385474B2 (ja) * 2017-03-13 2023-11-22 オカヴァ ファーマシューティカルズ， インコーポレイテッド 非ヒト哺乳動物にミコフェノール酸活性剤を送達すための方法および組成物
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
US20250282721A9 (en) * 2021-12-23 2025-09-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
WO2023224914A1 (en) * 2022-05-16 2023-11-23 Mayo Foundation For Medical Education And Research Assessing and treating caveolinopathy diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
ES2248793T3 (es) * 1993-10-01 2006-03-16 Roche Palo Alto Llc Suspensiones orales de alta dosis de mofetil micofenolato.
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
CN1233169A (zh) * 1996-10-14 1999-10-27 弗·哈夫曼-拉罗切有限公司 一种粉末状制剂的制备工艺
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
BR0306858A (pt) * 2002-01-10 2004-11-03 Novartis Ag Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma
JP2006511475A (ja) * 2002-09-18 2006-04-06 トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 脈絡膜新生血管症の抑制方法
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2007507458A5 (OSRAM)
WO2007014631A3 (de) Substrat, umfassend zumindest eine voll- oder teilflächige makrostrukturierte schicht, verfahren zu deren herstellung und deren verwendung
JP2005526058A5 (OSRAM)
WO2010042951A3 (en) Anti-reflective coatings comprising ordered layers of nanowires and methods of making and using the same
AR052186A1 (es) Composiciones de recubrimiento acuosas
WO2005091835A3 (en) A method and system for making a coated medical device
GB0513803D0 (en) Fabric care composition
WO2006014930A3 (en) Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
JP2005526147A5 (OSRAM)
WO2004069135A3 (en) Composition comprising a mixture of active principles, and method of preparation
DE50205419D1 (de) Verfahren zur Herstellung von Kieselsäure mit homogener Silyliermittelschicht
JP2008512527A5 (OSRAM)
TWI368627B (en) Silicon-containing antireflective coating forming composition, silicon-containing antireflective coating, substrate processing intermediate, and substrate processing method
WO2009122187A3 (en) Pharmaceutical composition
WO2020141789A3 (ko) 점착제 조성물, 이를 포함하는 점착제층 및 이를 포함하는 폴더블 디스플레이
EP1589082A4 (en) COATING COMPOSITION, ANTI-REFLECTION FILM, PHOTOLACK, AND PATTERN BASED THIS PRINTING METHOD
WO2013126874A3 (en) Seed coating composition and related methods
EP2093613A4 (en) SUPERIOR SURFACE ANTIREFLECTION FILM COMPOSITION, AND PATTERN FORMATION METHOD USING THE SAME
WO2009013356A3 (en) Anti-hiv tablet formulations comprising darunavir
TW200621331A (en) Method and kit for forming an outside layer on a curved surface
JP2008520195A5 (OSRAM)
JP2005522729A5 (OSRAM)
JP2009522138A5 (OSRAM)
EP2233978A4 (en) ANTIREFLECTIVE FILM FORMING COMPOSITION AND METHOD OF FORMING A PATTERN USING THE COMPOSITION
JP2006501374A5 (OSRAM)